News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Biopharmas should stop green lighting safe, mediocre candidates and focus on developing drugs that are genuine scientific breakthroughs to control spiralling R&D costs, according to industry guru Bernard Munos.
OncoMed Pharmaceuticals announced last week that the US Patent and Trademark Office granted its first US patent for technology to identify mAbs (monoclonal antibodies).
DISPATCHES FROM CPhI
A project to minimise the hold-up volume and losses in the fill/finish of biologics has reduced biologic waste ten-fold, says Cobra Biologics.